Physician profile
Betsy E Tanner
NPI 1295387751
$1,378.49
in general payments reported to CMS, 2019-2025
24 companies · $755 in 2025
The $755 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.51 · 2023: $304 · 2024: $223 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $210.65 | 2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $194.40 | 2025 | Tremfya |
| Amgen INC. | $93.22 | 2023-2025 | Repatha, Otezla, Evenity |
| Teva Pharmaceuticals USA, INC. | $89.14 | 2023 | Austedo Xr, Ajovy, Austedo |
| Astrazeneca Pharmaceuticals LP | $86.50 | 2024-2025 | Saphnelo, Farxiga, Breztri |
| Radius Health, INC. | $69.64 | 2025 | Tymlos |
| Genzyme Corporation | $68.90 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $68.70 | 2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $65.87 | 2023 | Rexulti |
| Lilly USA, LLC | $61.82 | 2021-2025 | Mounjaro |
| Abbvie INC. | $53.16 | 2021 | |
| Ani Pharmaceuticals, INC. | $41.88 | 2025 | Purified Cortrophin Gel |
| Idorsia Pharmaceuticals US INC | $41.50 | 2023 | Quviviq |
| Pfizer INC. | $38.83 | 2021-2023 | |
| Organon LLC | $27.23 | 2025 | Hadlima, Renflexis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.16 | 2023 | Freestyle Libre 3 |
| Aurinia Pharma U.S., INC. | $22.18 | 2025 | Lupkynis |
| Insmed, INC. | $21.87 | 2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.01 | 2025 | |
| Astellas Pharma US INC | $18.25 | 2024 | Veozah |
| Aspira Women'S Health INC | $17.95 | 2024 | Ova1 |
| Dexcom, INC. | $15.33 | 2023 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $14.86 | 2025 | |
| Exact Sciences Corporation | $14.44 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.